Hemogenyx Pharmaceuticals PLC Immuno-Oncology Summit Europe Presentation
May 16 2022 - 2:02AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
16 May 2022
16 May 2022
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Immuno-Oncology Summit Europe Presentation
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce
its participation in the Immuno-Oncology Summit Europe 2022, at
which Dr Vladislav Sandler will make a presentation entitled "
Anti-FLT3 CAR-T and Bispecific Antibody Therapies for Effective
Elimination of AML and Conditioning for Hematopoietic Stem Cell
Transplantation" . The conference assembles a wide range of thought
leaders from both academia and industry and will be held at Hilton
London Canary Wharf on 23-25 May 2022.
The Immuno-Oncology Summit is an important and influential
conference, and Hemogenyx Pharmaceuticals is very pleased to be
invited to make its presentation. This underlines the potential of
the Company's product candidates and gives it the opportunity to
draw the attention of a wide range of industry and academic leaders
in the field.
As part of his presentation, Dr Sandler will discuss the
properties and major advantages of two of the Company's product
candidates, its CDX bispecific antibody and HEMO-CAR-T, as
potential treatments for relapsed or refractory acute myeloid
leukemia and conditioning of patients for bone marrow
transplants.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented: "Our presentation at the
Immuno-Oncology Summit Europe 2022 provides the Company with a
great opportunity to inform the scientific, industrial and
investment communities about our achievements and increase the
Company's visibility globally. It also allows us to further
establish Hemogenyx Pharmaceuticals as a leader in the development
of medicines for the treatment of blood and autoimmune diseases.
"
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses
as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
About Immuno-Oncology Summit Europe 2022
The sixth Annual Immuno-Oncology Summit Europe returns to
London's Canary Wharf for three packed days of science and
technology, discussion and networking, with coverage of recent
advances in the development of promising immuno-oncology
treatments. The event is comprised of three conference programs
that cover therapeutic categories; T-Cell and related Cellular
Therapeutics; Bi-specific Antibodies; and Therapies targeting the
Tumour Microenvironment; while a fourth program covers strategies
for Therapeutic Development, including Predictive Biomarkers,
Preclinical studies and Translational Studies. Clinical results and
combination therapies will also be highlighted.
For more information visit
https://www.immuno-oncologyeurope.com/
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABKPBNQBKDFPD
(END) Dow Jones Newswires
May 16, 2022 02:02 ET (06:02 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Sep 2023 to Sep 2024